Solving Cancer Immunotherapy's Fuel Shortage with a Protected Sugar Source
UCLA researchers engineered T cells with two fungal proteins that let them import and metabolize cellobiose, a sugar tumors cannot use. This protected fuel restores T‑cell viability, cytokine production, and tumor‑killing capacity in glucose‑deprived environments. In mouse models of lung, breast and colorectal cancers, the modified cells slowed tumor growth, extended survival and even achieved complete regressions. The technique also rescued CAR‑T cells, suggesting a broadly applicable solution to the metabolic roadblock that hampers solid‑tumor immunotherapy.
FDA Approves Drug for Adult and Pediatric Patients Aged 6 and Older with Allergic Fungal Rhinosinusitis
The FDA has granted approval for Dupixent (dupilumab) to treat allergic fungal rhinosinusitis (AFRS) in adults and children six years and older, marking the first indication for this rare sinus disease. The approval follows a 52‑week trial that demonstrated significant...
Filkri Becomes Fifth FDA-Approved Neupogen Biosimilar
Accord BioPharma’s Filkri (filgrastim‑laha) received FDA approval as the fifth biosimilar to Amgen’s Neupogen. The indication set mirrors Neupogen’s, covering chemotherapy‑induced neutropenia, AML, bone‑marrow transplant, severe chronic neutropenia, and radiation‑induced syndrome. Approval was based on two randomized trials in healthy...
Sustained HIV Viral Suppression Restores Immune Potential: Victor Appay, PhD
New data presented at CROI 2026 show that people living with HIV who have maintained viral suppression for 25‑30 years on antiretroviral therapy regain robust HIV‑specific CD8⁺ T‑cell function. Using flow cytometry and single‑cell RNA sequencing, researchers found these cells display...
Verified Clinical Benefit | Cancer Accelerated Approvals
The FDA has granted traditional approvals to ten oncology drugs that originally received accelerated approval after post‑marketing studies verified clinical benefit. The list includes agents such as Braftovi, Epkinly, and Padcev, with conversion dates ranging from 2022 to 2026. These...
AI Must Model Dynamic Biology, Not Static Proteins
There is one major barrier blocking AI from truly reshaping biology and no one is talking about it. Biology is not static. Most AI breakthroughs so far have treated proteins, cells, and systems as frozen objects. That abstraction worked to get...
Biotech Embraces Data‑Driven Mornings, Gains Afternoons
I love that biotech has returned to the "data in the morning, raise in the afternoon" way of living its best life. $VIR $PVLA
Engineered Bacteria Can Consume Tumors From the Inside Out
University of Waterloo researchers have engineered the anaerobic bacterium Clostridium sporogenes to eat solid tumors from the inside out. By inserting an oxygen‑tolerant gene and coupling it to a quorum‑sensing circuit, the bacteria survive at the tumor periphery only after...
Former Pfizer CMO Joins $HELP, Credibility Boosted
$HELP adds former Pfizer CMO Dr. Freda Lewis-Hall to its board. Big pharma credibility bump. Now the pipeline has to earn it. https://t.co/CK7PsBE9B8
FDA Needs Clear Standards for Rare Disease Trials
If FDA is serious about moving with urgency in rare disease, the key question is evidentiary standards. Speed matters. But clarity on what constitutes “adequate and well-controlled” in ultra-small populations matters more. Predictability > rhetoric https://t.co/XVXg71NmGq
Holding Out Hope for HF Shunts, Even After an FDA Panel’s Doubts
The FDA Circulatory System Devices Panel rejected the V‑Wave interatrial shunt, citing a neutral primary endpoint in the RELIEVE‑HF trial despite promising subgroup results in HFrEF patients. The trial showed no overall reduction in mortality, hospitalizations, or quality‑of‑life measures, and...
Hepta‑refractory Myeloma Arises via Sequential CD38
The evolution to hepta-refractory myeloma involves sequential loss of CD38, BCMA and GPRC5D [Feb 17, 2026] Riedhammer et al. @LeukemiaJnl https://t.co/EyGBz7sEQz #mmsm #PrecisionMedicine #caxtx
Future Wedbush Take on ABVX M&A Will Be Hilariously Absurd
Looking forward to dusting off some of these absolutely asinine takes from the Wedbush report after $ABVX M&A. It’ll be even funnier then than it is today. Until then, 🥱
STAT+: Drugmakers Lay Out Their Legal Arguments Against Trump’s Drug Pricing Experiments
Pharmaceutical and biotech firms are mobilizing against two Trump administration proposals that would tie Medicare drug prices to those paid in other affluent nations. The initiatives – the GLOBE model for Part B physician‑administered drugs and the GUARD model for Part D...
What to Know About the ‘Anti-Aging’ Peptide Shots Flooding Social Media
A wave of unapproved anti‑aging peptide injections is sweeping social media, driven by influencers and celebrities. Most products are sold on the gray market, often from China, and lack FDA approval or robust clinical data. Experts warn of safety risks,...
Pharmaceutical Executive Daily: Novo Nordisk Announces Price Reductions for GLP-1 Products
Novo Nordisk announced steep price cuts for its GLP‑1 diabetes and obesity drugs, aiming to broaden patient access amid intensifying pricing scrutiny. AbbVie is committing $380 million to expand API manufacturing capacity, reinforcing supply‑chain resilience. Bora Pharmaceuticals and GSK sealed a...
Vir Surges After Astellas Partnership and T‑cell Data
Vir climbs on Astellas deal, study results for ‘masked’ T cell engager https://t.co/336c9FJdjt by @Lilah_Alvarado $VIR + 27% $JANX $ALPMY
Novo Slashes GLP‑1 Prices; Palvella Spikes on Data
Novo to cut GLP-1 drug prices; Palvella soars on study data https://t.co/UAs4IETgPX $NVO $PVLA+ 32% $GOSS $VNDA $PFE #biotech
Thermogeneration by White Fat Could Be Used to Treat Obesity
Researchers at Cornell uncovered a previously unknown thermogenic pathway in white adipocytes, where free fatty acids induce proton leakage through the mitochondrial ADP/ATP carrier (AAC). This AAC‑mediated uncoupling mirrors brown‑fat heat production without involving UCP1. In mouse models, enhancing intracellular...
Roctavian Withdrawn, Exposing Science‑to‑market Gap
Failing to find a buyer, BioMarin is voluntarily withdrawing Roctavian from the market. A fitting end for what was once one of the highest-profile gene therapies in development — and a reminder of the gap between promising science and a viable...
Novo Highlights New Data on Triple‑Target Obesity Therapy
Novo, searching for a spark, spotlights new data for three-pronged obesity drug https://t.co/pPo9Oc1wlF $NVO $LLY #obesity
MRNA Nanobodies Show Promise in Colorectal Cancer
A preclinical study published in eGastroenterology demonstrates that lipid‑nanoparticle delivery of nucleoside‑modified mRNA encoding anti‑PD‑L1 nanobodies suppresses tumor growth in mouse models of both sporadic and colitis‑associated colorectal cancer. Researchers engineered monomeric and quadruple nanobody formats; the quadruple construct showed...
FDA Draft Guidance Boosts Individualized Therapy Innovation
FDA Issues Plausible Mechanism Pathway Draft Guidance to Spur Innovation for Individualized Therapies https://t.co/OZW6Q27zMa via @Inside_PM
Single-Cell RNA‑seq Isn’t Always Necessary—Choose Wisely
1/ 🧵 No, you do not always Need Single-Cell RNA-seq Single-cell RNA-seq is popular and powerful, but it's not always the best choice. Here's why you should think carefully before diving in. https://t.co/E9DdeHI4b6
Pfizer’s Strategy: How the Company Is Evolving After Its COVID Success
Pfizer’s post‑COVID strategy pivots from vaccine and antiviral sales to rebuilding growth through oncology and metabolic assets. The 2026 guidance excludes COVID revenue, projects modest 4% operational growth, and anticipates a $1.5 billion patent‑cliff hit. To offset these pressures, Pfizer completed...
Immedica Secures Accelerated Approval, Plans PRV Sale
Immedica wins accelerated approval for once-rejected rare disease drug, plans to sell PRV - https://t.co/wU3AfqQzjw
Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer
Natera reported Phase 2 SINERGY trial results showing a 63% objective response rate in recurrent or metastatic head and neck squamous cell carcinoma when treatment was adapted using Signatera circulating tumor DNA monitoring. Seventy‑four percent of the 27 patients were de‑escalated...
AI Provides a More Precise Time of Death Post-Mortem
Researchers at Linköping University and Sweden's National Board of Forensic Medicine have created an AI model that estimates the post‑mortem interval with roughly one‑day precision, even up to 13 days after death. The system analyzes metabolite patterns in blood, leveraging...
Budapest’s Turbine Secures $25M to Simulate Lab Experiments
The latest AI biotech raise comes not from the Bay Area or Boston, but out of Budapest Turbine has closed a $25M Series B, planning to build AI models that can simulate more and more lab experiments: https://t.co/Q31DVENA9G
Slate Secures $130M, Launches Chinese Headache Drug
Slate starts up with $130M and a headache drug from China https://t.co/6DEltQAI8s by @gwendolynawu #biotech #startups $HLUBF
Sciwind Biosciences and Pfizer China Partner to Commercialize Ecnoglutide in China
Sciwind Biosciences granted Pfizer China exclusive rights to commercialize ecnoglutide injection in Mainland China. Sciwind will keep the marketing authorization and handle R&D, registration, manufacturing, and supply, receiving up to $495 million in milestone payments. Ecnoglutide, a cAMP‑biased GLP‑1 receptor agonist,...
NVO Triple G Shows Higher 24‑Week Response Than LLY
Cross trial and China data caveats, but 19.7% at 24 weeks for $NVO triple G looks quite good. Probably a few % points better than $LLY triple G at 24-week timepoint. https://t.co/ylgf4vTEOq
Distribution of Mitochondria Is Connected to Function in Aging Neurons
Researchers using Drosophila models demonstrated that proper distribution of mitochondria along axons is essential for neuronal autophagy and protein homeostasis. Depleting axonal mitochondria triggers protein accumulation, autophagic failure, and a shift in eIF2β expression that suppresses global translation. Overexpressing eIF2β...
ArisGlobal Launches XDI
ArisGlobal unveiled XDI, a Data Intelligence Cortex that federates fragmented life‑science data without centralizing it. The platform delivers continuous, explainable, decision‑grade intelligence across domains such as pharmacovigilance, benefit‑risk, and regulatory operations. XDI promises up to 80% reduction in compliance effort...
Camel Antimicrobials Could Get Us over the Hump of Antibiotic Resistance
Researchers at Sultan Qaboos University have isolated three antimicrobial peptides from dromedary camels, with CdPG-3 and CdCATH showing potent activity against methicillin‑resistant Staphylococcus aureus and multidrug‑resistant Escherichia coli. The peptides kill bacteria by disrupting their membranes while exhibiting low toxicity...
MiraDx Launches New PROSTOX Genetic Test for Prostate Cancer Patients
MiraDx has launched PROSTOX Standard, a clinically validated genetic test that predicts long‑term urinary toxicity for prostate cancer patients receiving conventional or moderately hypofractionated radiation therapy. The test uses a cheek swab and returns results in five to seven days,...
Revealing the Structural Fingerprints of Disease: Q&A with Faraz Choudhury
Immuto’s CEO Faraz Choudhury explains that conventional target discovery, which focuses on gene mutations and protein abundance, overlooks disease‑specific protein conformations. The company’s platform maps surface protein conformations (SPCs) in living, patient‑derived models using high‑resolution mass spectrometry and AI‑driven analysis,...
FDA Grants Breakthrough Designation to Orthonika’s Synthetic Total Meniscus Implant
Orthonika, an Imperial College London spin‑out, received FDA Breakthrough Device Designation for its synthetic Total Meniscus Replacement (TMR) implant and an invitation to the Total Product Life Cycle Advisory Program. The designation promises prioritized regulatory engagement, speeding the path to...
FDA Accepts Beren Therapeutics’ NDA for Niemann-Pick Disease
Beren Therapeutics announced that the U.S. Food and Drug Administration has accepted its New Drug Application for adrabetadex, an investigational therapy aimed at treating infantile‑onset Niemann‑Pick disease type C (NPC). The agency set a target action date of 17 August 2026 under the...
How Bacteria Can Reclaim Lost Energy, Nutrients and Clean Water From Wastewater
Researchers in a Frontiers in Science review highlight that global wastewater contains roughly 800,000 GWh of recoverable chemical energy and nutrients enough to meet 11 % of ammonia and 7 % of phosphate demand. Microbial electrochemical technologies (METs) using electrogenic bacteria can transform...
STAT+: New Treatment Approach Could Give IBD Patients Hope, and Be a Bonanza for Drugmakers
A new combination‑therapy approach for inflammatory bowel disease (IBD) aims to boost remission rates beyond the current 30 % success benchmark. By pairing agents that target distinct immune pathways, early trials show remission climbing to roughly 55 % and faster mucosal healing....
Advancing Pediatric MASLD Screening: Challenges and Future
A forthcoming Pediatric Research review by Vimalesvaran and Dhawan examines the current state of Metabolic Dysfunction‑associated Steatotic Liver Disease (MASLD) screening in children, highlighting advances in imaging and biomarker research while exposing persistent gaps in sensitivity and guideline standardization. The...
Every Cure and Computational Pharmacophenomics: A New Field of Medicine
The nonprofit Every Cure is launching computational pharmacophenomics, an AI‑driven approach that systematically evaluates all 4,000 FDA‑approved drugs for the 14,000 diseases lacking treatments. Its MATRIX platform integrates massive biomedical knowledge graphs, generates graph embeddings, and ranks 75 million drug‑disease pairs,...
Comparing Senescence in Articular Chondrocytes: Phenotype & Molecules
Researchers published a comparative analysis of replicative versus chemically‑induced senescence in articular chondrocytes, revealing divergent molecular signatures, secretory profiles, and mitochondrial dynamics. Replicative senescence displayed a controlled, anti‑inflammatory SASP and stable epigenetic marks, while chemically‑induced senescence produced a pro‑inflammatory secretome,...
New Research Reveals Dry Powder Inhalers Enhance Patient Outcomes and Reduce Environmental Impact
UCLA Health researchers published a JAMA Internal Medicine study showing that dry powder inhalers (DPIs) and soft‑mist inhalers (SMIs) cut COPD exacerbations while eliminating high‑global‑warming‑potential propellants used in metered‑dose inhalers (MDIs). The analysis of insurance‑claims data from 2016‑2025 found a...
Hims Reports 2025 Earnings, Shares Details on GLP-1 Pill Decisions
Hims & Hers disclosed its fourth‑quarter earnings and announced that it has withdrawn the controversial GLP‑1 weight‑loss pill it briefly launched. The decision followed conversations with key ecosystem stakeholders, including regulators and partner pharmacies. The company highlighted modest revenue growth...
Geometrically Well‐Controlled Wireframe RNA Nanostructures With Bundled‐Helix Edges
Researchers have introduced a single‑stranded RNA origami platform that uses dual duplex bundles as wireframe edges, delivering markedly defined geometries. The approach enables the construction of intricate RNA polygons and grid lattices with high yield and structural fidelity. By bundling...
Kinase-Inactive RIPK3 Model Unveils Scaffold Role in Inflammation
Researchers created a kinase‑inactive RIPK3 D143N mouse that remains viable, revealing that RIPK3’s scaffold function alone can drive TNF‑induced inflammatory pathology. The mutant protein continues to recruit RIPK1, FADD and activate NF‑κB, producing cytokine storms without necroptotic cell death. In...
Assessing Targeted HIV and Harm Reduction Services
A new NIH‑backed assessment of targeted HIV prevention and harm‑reduction services in five major U.S. cities shows a 15% decline in new infections over the past year. The study attributes the drop to expanded syringe‑exchange programs, mobile testing units, and...
Cut Down on Oncology Drug Waste With Better Forecasting
Oncology drug waste reaches up to 30%, costing over $2 billion annually in the U.S. A 2023 CMS rule now forces manufacturers to refund Medicare for discarded volumes beyond a 10% threshold, adding financial pressure. Traditional forecasting relies on static sales...